Search

Displaying results 3471 - 3480 of 10000 in total
  1. Drug

    Dexmedetomidine

    go.drugbank.com/drugs/DB00633
    ApprovedInvestigationalVet approved

    An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine.

    Products: Dexmedetomidine in Dextrose, Dexmedetomidine Hydrochloride in Sodium Chloride
  2. Drug

    DG041

    go.drugbank.com/drugs/DB05027
    Experimental

    DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. … It block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk.

  3. Drug

    Ecraprost

    go.drugbank.com/drugs/DB16148
    Investigational

    Ecraprost is under investigation in clinical trial NCT00059657 (Efficacy/safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease).

  4. Drug

    1-Palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol))

    go.drugbank.com/drugs/DB11331
    ApprovedWithdrawn

    Palmitoyloleoyl-phosphatidylglycerol was a component of Surfaxin, discontinued in 2017, which acted as a surfactant [FDA Label].

    Salts: 1-palmitoyl-2-oleoyl-sn-glycero-3-(phospho-rac-(1-glycerol)), sodium saltSynonyms: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol, 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphatidylglycerol
  5. Drug

    Crovalimab

    go.drugbank.com/drugs/DB16128
    ApprovedInvestigational

    [A263958] It soon gained its approval in Japan in the next month,[A263958] and in the USA in June of the same year. … [L50908] First developed by Chugai Pharmaceutical, in collaboration with Roche, crovalimab was first approved in China in February 2024 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).

  6. Drug

    Flufenamic acid

    go.drugbank.com/drugs/DB02266
    Approved

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p16) … An anthranilic acid derivative with analgesic, anti-inflammatory, and antipyretic properties. It is used in musculoskeletal and joint disorders and administered by mouth and topically.

  7. Drug

    Benfotiamine

    go.drugbank.com/drugs/DB11748
    ApprovedInvestigationalWithdrawn

    Benfotiamine has been investigated for the treatment and prevention of Diabetic Nephropathy and Diabetes Mellitus, Type 2.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Dihydroergocristine

    go.drugbank.com/drugs/DB13345
    Approved

    [L2637] It is a semisynthetic ergot alkaloid and thus, it is characterized by a structural skeleton formed by an alkaloid ergoline.

  9. Drug

    Rubidium Rb-82

    go.drugbank.com/drugs/DB09479
    ApprovedInvestigational

    It is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected

  10. Drug

    Sunvozertinib

    go.drugbank.com/drugs/DB18925
    Investigational

    [A274143] Sunvozertinib was granted accelerated approval in the US on July 2, 2025 for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor … Sunvozertinib is an irreversible and selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor.

    Synonyms: 2-Propenamide, N-[5-[[4-[[5-chloro-4-fluoro-2-(1-hydroxy-1- methylethyl)phenyl]amino]-2-pyrimidinyl]amino]-2-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-4-methoxyphenyl]-, N-{5-[(4-{[5-chloro-4-fluoro-2-(1-hydroxy-1-methylethyl)phenyl]amino}pyrimidin-2-yl)amino]-2-[(3R)-3-(dimethylamino)pyrrolidin-1-yl]-4-methoxyphenyl}prop-2-enamide